New in 2025 – Prostate Cancer Treatment – Doctors, Innovations, Clinical Trials

Prostate cancer remains a significant health concern in Israel and abroad, making it the most prevalent cancer among men.
In 2025, Israel continues to lead in innovative treatments and research, offering advanced options in surgery, radiotherapy, and clinical trials

Prostate Cancer Treatment in 2025: Innovations, Breakthroughs, and Hope in Israel

Best Israeli Doctors for Prostate Cancer in Israel

It is recommended to be treated by an experienced, prostate cancer focused specialists. 

Israel boasts a cadre of esteemed professionals dedicated to prostate cancer treatment. Here are some of the leading doctors and institutions specializing in prostate cancer care in Israel in 2025 – oncologists, surgeons, radiologists, pathologists, radiation oncologists.

We collaborate with such worldwide known prostate cancer specialists as Prof. Raanan Berger, Dr. Eli Rosenbaum, Prof. Jack Baniel and many others.

• your medical summary, including treatments and results
• medical files
• blood tests
• pathology reports
• PET CT, MRI reports in English and CDs.

We will promptly organize consultation.

Based on the results of the consultation, we will provide you with a doctor’s report with treatment recommendations.

⇒ Oncologist’s Report Example

The main treatments for Prostate cancer are Active and passive observation / Surgery – radical prostatectomy /External radiation therapy /Internal radiation therapy (brachytherapy) /Focal treatments / Systemic treatments /Hormonal therapy / Chemotherapy in combination with other treatments /Immunotherapy /Treatment to relieve symptoms.

Surgical Innovations in 2025

Israeli hospitals are at the forefront of minimally invasive surgical techniques:

• Robotic-Assisted Surgery: Surgeons utilize the latest Da Vinci Xi surgical robot to perform precise, nerve-preserving prostatectomies. This technology enhances surgical accuracy, offering high precision and reducing risks such as sexual dysfunction. The system provides 3D imaging and eliminates hand tremors, enhancing surgical outcomes. Robotic surgery reduces recovery time and minimizes complications.

Innovations in Radiotherapy

Israeli medical centers have made notable advancements in radiotherapy for prostate cancer:

• High Dose-Rate (HDR) Brachytherapy: This novel procedure involves inserting thin tubes into the prostate gland to deliver targeted radiation, effectively destroying cancer cells with minimal side effects. The precision of HDR brachytherapy reduces damage to surrounding tissues and decreases the number of required sessions.
• Reduced Radiation Sessions: A pioneering study led by Dr. Elisha Freedman from Beilinson Hospital demonstrated that delivering high-dose external beam radiation therapy in just two sessions is as effective as the traditional five-session protocol. This approach not only maintains efficacy but also lessens patient burden and enhances treatment capacity.
• More about radiotherapy for prostate cancer in Israel 

Emerging Therapies and Clinical Trials

Israel is actively involved in developing and implementing cutting-edge therapies:

• Lutetium-177 PSMA Therapy: This targeted treatment involves injecting radiopeptides that bind to prostate-specific membrane antigens (PSMA) on cancer cells, delivering localized radiation to destroy them. Sheba is among the few centers worldwide offering this advanced therapy.
• POPSTAR II Clinical Trial: Sheba Medical Center has joined the Peter MacCallum Cancer Center for the POPSTAR II trial, comparing Lutetium PSMA therapy and stereotactic ablative radiotherapy (SABR) for advanced prostate cancer. This collaboration aims to enhance treatment options and outcomes. 

Other Treatment Methods 

Israel’s commitment to innovation and excellence in prostate cancer treatment offers patients access to state-of-the-art therapies and world-class medical expertise.

• SpaceOAR hydrogel – A water-based preparation designed to temporarily separate the anterior rectal wall from the prostate during radiation therapy for prostate cancer. Creating this space reduces the radiation dose received by the anterior rectum and the risk of intestinal symptoms as a result of radiation therapy. The preparation is injected as a liquid into the space between the prostate and the rectum, separating the organs then crystallize into a soft hydrogel. The gel remains stable for three months during radiation treatment and then dissolves and is completely absorbed by the body. 
• Cryotherapy – performed under general anesthesia or with an anesthetic injection into the back. Several metal transducers are inserted through the skin into the area of ​​the prostate tumor, containing liquid nitrogen, which freezes and destroys the tumor. Although the procedure is done under local anesthesia, you may experience pain, but this can be managed with painkillers. After freezing, a tube (catheter) is inserted into the bladder through the abdomen to drain urine. The catheter is removed about one to two weeks after treatment. Cryotherapy can be used to treat men with early, low-risk prostate cancer who are not suitable for surgery or radiation therapy. However, most doctors do not use cryotherapy as the first treatment for prostate cancer. Compared to the “standard” treatments, which are surgery or radiation therapy, there is currently less information about the long-term effectiveness of cryotherapy.
• High-Intensity Focused Ultrasound (HIFU) – the ultrasound transducer (a device that receives and transmits sound waves) is inserted through the anus into the rectum, maps the prostate gland, and transmits high-intensity focused sound waves that produce localized heat and treat the tumor. The transducer is surrounded by a cooling balloon that protects the rectal wall. This treatment is given under general or local anesthesia, and after a short recovery and observation, the patient is discharged home. The accuracy and real-time monitoring reduce side effects, such as erectile dysfunction and urinary leakage. Because the treatment is non-invasive and does not use ionizing radiation, there is no bleeding or side effects typical of radiation treatments. HIFU is suitable for patients with early-stage tumors as an alternative to surveillance, surgery, or radiation, or for those whose disease has returned after radiation therapy, when the tumor is still limited to the prostate area. This treatment is relatively new, and there are still no long-term results and follow-up regarding its effectiveness.
• Electric current therapy (Nano Knife) – use of electric current passing through thin electrodes that surround the tumor and damage the integrity of its cell membranes. The goal of the treatment is to create holes in the membrane walls and thus destroy the cancer cell. The operation is performed as a day hospital and is done under general anesthesia. First, the tumor area is marked using MRI, then several thin needles (electrodes) are inserted through the skin into the prostate under ultrasound guidance, so that they surround the tumor area. The electric current is transmitted between pairs of electrodes. The method is still very new in the treatment of prostate cancer and is considered experimental.

Oncotests to determine the type of treatment for Prostate Cancer in 2025

There are several tests that can be used as an aid in choosing the type of treatment. These are genomic tests of the biopsy tissue, which aim to provide more accurate information about the subject’s risk level and thus help in making a treatment decision.

• Genomic Prostate Score Oncotype DX – GPS is a genomic test that examines the expression of 17 different genes associated with prostate cancer, and is intended for patients with localized prostate cancer. The test is performed on tissue that has already been taken from the biopsy and provides information on the aggressiveness of prostate tumors, including those that were not sampled, predicts the risk of developing metastases and the risk of dying from prostate cancer. In low- and intermediate-risk patients, the test results help make a treatment decision about active surveillance or immediate local treatment. In intermediate- and high-risk patients, the test can help make a decision about the need for combination therapy.
• Prolaris is a genomic test that analyzes changes in 46 genes in prostate biopsy tissue and provides a risk score to help predict the likelihood of disease progression in men with localized prostate cancer. The test is designed to help choose the appropriate treatment in cases of low-grade and sometimes even moderate-grade prostate cancer: whether it is active surveillance without surgery or radiation, or active treatment, i.e. surgery or radiation therapy. The test can also help in deciding whether to provide adjuvant hormonal therapy in high-risk patients after surgery or radiation therapy.
• Decipher – a genetic test based on 22 genetic markers and can help decide who is a suitable candidate for active surveillance and who needs treatment. The test is performed on excised prostate tumor tissue. The test can also determine whether patients who have received radiation therapy for prostate cancer or prostatectomy may benefit from the addition of hormonal therapy or whether this treatment can be dispensed with without risk of worsening.
• 4KScore – a blood test that checks the level of four biomarkers (biological markers that raise suspicion of prostate cancer). The biomarkers are: total PSA, free PSA, bound PSA and hK2. The test can help in certain cases where PSA values ​​are high, to decide whether a prostate biopsy is necessary. The test is also intended for subjects who have undergone a biopsy that turned out to be normal, but there is still a concern about prostate cancer.
• Onco-test ProMark Prostate – test is done on prostate biopsy tissue, predicts cancer aggressiveness* in patients with biopsy Gleason Scores of 3+3 and 3+4. It provides a personalized prediction that the cancer can be managed without aggressive treatment, or an indication that aggressive therapy may be appropriate, objective and fully reproducible, outperforms and requires substantially less tissue than conventional gene-expression-based Prostate Cancer prognostic tests.

Clinical Trials in Israel in 2025

According to the Israeli Ministry of Health my.health.gov.il

• A Phase 3, Randomized, Open-Label Study of MK-5684 Versus Alternative Therapy with Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with a Next-Generation Hormonal Agent (NHA) and Taxane-Based Chemotherapy (MK-5684-003)
• A Comparative Study to Evaluate PET FAPI as a Tool for Screening and Monitoring Urological Malignancies
• A Phase 3, Randomized, Open-Label Study of MK-5684 Versus Alternative Therapy with Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on or After Prior Therapy with a Single Next-Generation Hormonal Agent (NHA)
• Use of PSMA PET-CT as a Diagnostic Tool for Early-Stage Prostate Cancer Detection
• Characterization of Tumor Cell Genetic Material As a prognostic, predictive, and treatment monitoring tool in cancer patients
• A phase 3 randomized, double-blind study of pembrolizumab (MK-3475) in combination with docetaxel and prednisone versus placebo in combination with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) who were not treated with chemotherapy and whose disease progressed while on treatment with a next-generation hormonal agent (NHA) (KEYNOTE-921)
• Evaluating the added value of PET-MR in the diagnosis and follow-up of tumors in oncological diseases compared with PET CT
• A phase 1 open-label, non-randomized, multicenter study to evaluate the biodistribution of radium-223 in patients with castration-resistant prostate cancer (CRPC) with bone metastases receiving radium-223 therapy dichloride.
• A phase 4, randomized, open-label, multicenter study to evaluate the efficacy and safety of standard doses of radium-223 dichloride versus standard doses of novel antihormonal therapy in patients with castration-resistant prostate cancer with bone metastases who had progressed on/after one line of novel antihormonal therapy.
• Primary Protocol MK-5684-U01: A Phase 1/2 Platform Study to Evaluate the Safety and Efficacy of MK-5684-Based Investigational Therapies in Subjects with Prostate Cancer Substudy MK-5684-01A: A Phase 1/2 Umbrella Substudy of the Primary Protocol MK-5684-U01 to Evaluate the Safety and Efficacy of MK-5684-Based Combination Therapies or MK-5684 Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of ODM-201 Versus Placebo as Add-On to Standard of Care Androgen Depletion and Docetaxel in Patients with Hormone-Sensitive Metastatic Prostate Cancer
• An Open-Label Phase 2 Extension Study for Subjects with Prostate Cancer Previously Participating in a Clinical Trial of Enzalutamide
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Telazoprib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
  A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab Compared to a Second Novel Hormonal Therapy (NHT) in Patients with Metastatic Castration-Resistant Prostate Cancer
• Cancer Diagnosis by Breath Test
• An Open-Label Study to Treat Patients with Newly Diagnosed Glioblastoma to Evaluate the Safety and Tolerability of Enzalutamide in Combination with Standard of Care
• A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Trastuzumab Druxecan (T-DXd) in Combination with Immunotherapy, with and without Chemotherapy, for the First-Line Treatment of Patients with Lung Cancer Advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (DESTINY-Lung03)
  APOLLO – A randomized, double-blind, phase II study evaluating olaparib versus placebo after treatment for curative intent in patients with resected pancreatic cancer harboring a pathogenic mutation in the BRCA1, BRCA2, or PALB2 genes
• A phase 3 trial of docetaxel versus docetaxel and radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
• A Phase 3, International, Multicenter, Prospective (Preliminary), Open-Label, Randomized Study Comparing Lutetium-177 Vibiobutide Tetraxane (AAA617) Treatment vs. Observation for Delaying Castration or Disease Recurrence in Adult Patients with Prostate-Specific Membrane Antigen-Positive, Oligometastatic Prostate Cancer (CAAA617D12302)
• A Phase 2/3, Multicenter, International, Open-Label, Randomized Study Evaluating AAA817 vs. Standard of Care in Adult Participants with Prostate-Specific Membrane Antigen (PSMA)-Positive, Castration-Resistant, Metastatic Prostate Cancer Who Progressed During or After Targeted Lu-PSMA Therapy. (CAAA817A12201)
• Evaluating the Efficacy and Safety of Derulotamide (ODM-201) in Men with High-Risk, Castration-Resistant Non-Metastatic Prostate Cancer
• A Study to Evaluate the Efficacy and Safety of JNJ-56021927 (Aplotamide) in the Treatment of Subjects with High-Risk Prostate Cancer Receiving Initial Radiation Therapy: ATLAS
• A Phase II Trial of Pembrolizumab (MK 3475 Pembrolizumab) for the Treatment of Subjects with Metastatic, Hormone-Resistant Prostate Cancer (mCRPC) Who Have Previously Been Treated with Chemotherapy
• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Ipsertab in Combination with Abiraterone and Prednisone/Prednisolone Compared with Placebo in Combination with Abiraterone and Prednisone/Prednisolone in Older Men Patients with previously untreated, asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer
• Efficacy and safety study of niraparib for the treatment of men with metastatic castration-resistant prostate cancer with DNA repair defects
  A phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) in combination with enzalutamide versus placebo in combination with enzalutamide in subjects with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641).
• An open-label, dose-escalating phase 1b study of neftemumab astapantox (ABR-217620) in combination with durvalumab (MEDI4736), including cohort expansions, in subjects with selected advanced or metastatic solid tumors.
• A phase 3, randomized, placebo-controlled, double-blind study of aflatoxin in patients with high-risk, locally advanced or locally advanced prostate cancer who are candidates for total prostatectomy
• Neoadjuvant treatment with lutetium-177 in patients with high-risk prostate cancer who are candidates for radical prostatectomy; Feasibility Study
• A Phase 2 Randomized Study Comparing Degarelix to a GnRH-Agonist in Patients with Advanced Prostate Cancer Receiving Combined Hormonal Therapy
• BP007 BioProtect Biodegradable Balloon Implant System for Prostate Cancer Patients Elected for Radiation.
• A Study of Niraparib in Combination with Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPS) Who Have a Germline Deletion Mutation or a Somatic Mutation in the Homologous Recombination (HRR) DNA Repair Pathway.
• A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Capivasertab in Combination with Abiraterone vs. Placebo in Combination with Abiraterone for the Treatment of Patients with Primary (De Novo) Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by a Defect in PTEN (CAPItello-281).
• Silybinin (milk thistle) treatment for the prevention of brain metastases in high-risk patients after radiosurgery
• A multicenter, randomized, double-blind, double-dummy, parallel-group study of variable duration from 24 to 52 weeks to evaluate the efficacy and safety of a metered-dose inhaler (MDI) containing budesonide, glycopyrronium, and formoterol fumarate versus an MDI containing budesonide and formoterol fumarate and a high-pressure MDI containing Symbicort in adult and adolescent participants with inadequately controlled asthma (LOGOS)
• A pivotal, multicenter, phase 3 study to evaluate the safety and efficacy of TOOKAD (pedaliporfin), a vascular-targeted photodynamic therapy, in the treatment of low-grade upper urinary tract urothelial cell carcinoma
• A study of XL092 in combination with immuno-oncology drugs in subjects with solid tumors (STELLAR-002)
• A retrospective medical record review to describe the safety of Lutetium-177 prostate-specific membrane antigen-targeted therapy in patients with metastatic castration-resistant prostate cancer previously treated with radium-223
• Two versus five stereotactic radiotherapy treatments for locally advanced low-risk and intermediate-to-low-risk prostate cancer. A prospective study.
• A phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of capispertib in combination with docetaxel versus placebo in combination with docetaxel as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) (CAPItello-280).
• A prospective Phase II trial to evaluate radiation dosimetry of JDI-PSMA-11 in patients with prostate cancer for comparison with radiation dosimetry data from the FDA-approved RLD (comparative drug).
• A first-in-human Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of ABBV-969 in adult patients with metastatic castration-resistant prostate cancer.
• Radioguided Surgery Using Tc99m-PSMA-ligands in Patients with Prostate Cancer
• A Phase 2/3, Randomized, Double-Blind, Controlled Trial of Zenselintinib (XL092) in Combination with Pembrolizumab vs. Pembrolizumab as First-Line Treatment for Subjects with PD-L1-Positive Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• Spiser Hydrogel Injection Prior to Cryotherapy for Localized Prostate Cancer: A Phase I Feasibility Trial
• An Open-Label Platform Study for Crossover, Continued Treatment, and Ongoing Safety Monitoring of Participants: ISA-8 Specific Addendum for a Long-Term Extension Study of Study 70218902EDI1001
• A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride in Combination with Exemestane and everolimus versus placebo in combination with exemestane and everolimus for the treatment of subjects with HER2-negative, hormone receptor-positive metastatic breast cancer with bone metastases
• A study of olaparib versus enzalutamide or abiraterone acetate for men with metastatic castration-resistant prostate cancer (PROfound study)
• Somatostatin therapy in patients with hormone-refractory prostate cancer who demonstrate neuroendocrine differentiation on 68Ga-DOTA-TATE imaging
• An open, prospective, non-randomized study of 3D navigation technology for improved performance of prostate biopsy procedures in cases of repeat biopsies and active surveillance.
• TRITON2: A Phase 2, Multicenter, Open-Label Study of Rocaparib in Patients with Homologous Recombination-Deficiency-Related Metastatic Castration-Resistant Prostate Cancer
• A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enzalutamide Plus Androgen Depletion Therapy (ADT) vs. Placebo Plus ADT in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
• A Study to Evaluate the MRI-US Fusion Prostate Biopsy Procedure – Transperineal vs. Transrectal Approach
• Efficacy of F18-PSMA-1007 PET/CT in Assessing the Extent of Disease in Patients with Intermediate-High Risk Prostate Cancer at Diagnosis, Correlation of Findings with Histopathology and Comparison with Ga68-PSMA PET/CTA prospective, randomized, controlled trial of dutasteride in reducing recurrence rates in non-muscle invasive bladder cancer
• A phase 1b-2 study of combination therapies with niraparib in metastatic castration-resistant prostate cancer
• A phase 3, randomized, multicenter trial of cabazitaxel and pelvic radiation in patients with localized prostate cancer with high-risk features for recurrence.
• A study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in candidates with metastatic castration-resistant prostate cancer.
• A randomized, open-label phase 3 trial of pembrolizumab in combination with olaparib versus abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer, regardless of the presence of homologous recombination DNA repair defects, who had failed one next-generation hormonal agent and chemotherapy (MK7339-010)
• A randomized, double-blind phase 3 trial of pembrolizumab (MK-3475) in combination with enzalutamide and androgen suppression versus placebo in combination with enzalutamide and androgen suppression in patients with metastatic hormone-sensitive prostate cancer (mHSPC) (KEYNOTE-991).
• A combination of 68Ga-PSMA PET imaging and magnetic resonance spectroscopy for the assessment of prostate cancer.
• A Phase 3, Double-Blind, Randomized Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Castration-Resistant Metastatic Prostate Cancer
• A First-in-Human, Open-Label, Dose-Escalation Study with Extended Follow-Up to Evaluate the Safety of GEN1044 in Subjects with Malignant Solid Tumors.
• A Phase 1 Study of JNJ-70218902, a Novel T-Targeting Compound, for the Treatment of Advanced Solid Tumors. A feasibility study of preoperative alpha-beam brachytherapy in men with preoperative prostate cancer
• A phase 4, randomized, open-label, multicenter study to evaluate the efficacy and safety of standard doses of radium-223 dichloride versus standard doses of novel antihormonal therapy in patients with castration-resistant prostate cancer with bone metastases who have progressed on or after one line of novel antihormonal therapy.
• CATCH-R: A follow-up study providing continued access to rocaparib clinical treatment
• Comparison of small bowel and bladder toxicity during preoperative radiation therapy in rectal cancer patients by position: supine or prone.
• A single-arm, open-label extension study to continue darolutamide in participants recruited from previous Bayer-sponsored studies (ROS study)
• Neurovascular plexus (NVB) preservation with MRI-accelerated prostate radiation in targeted prostate cancer
• I3Y-MC-JPEG protocol: A phase 3, randomized, double-blind, placebo-controlled study of abamaciclib in combination with abiraterone and prednisone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC).
• 18FDHT-CT PET imaging as a tool for assessing treatment efficacy in breast cancer patients.
• A study of niraparib in combination with abiraterone acetate and prednisone compared with abiraterone acetate and prednisone in candidates with metastatic castration-resistant prostate cancer.
• A Phase 3, Double-Blind, Placebo-Controlled, Randomized Trial of Derulotamide in Combination with Androgen Depletion Therapy (ADT) vs. Placebo in Combination with ADT in Patients with High Risk of Biochemical Recurrence (BCR) of Prostate Cancer
• A Phase 2, Open-Label, Randomized Trial of Lu-PSMA in Combination with SABR Radiation Therapy in Patients with Oligometastatic Prostate Cancer.
• A Feasibility Study of Alpha Brachytherapy in Men with Locally Recurrent Prostate Cancer. Neoadjuvant Terbium Therapy in Patients with High-Risk Prostate Cancer Candidates for Radical Prostatectomy; Feasibility Study